Developmental Research Program

发展研究计划

• 批准号: 8999526
• 负责人: Timothy Charles Thompson
• 金额: $ 7.52万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-02 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8999526
• 关键词: Area; Award; Awareness; Basic Science; Cancer Center; Cancer Patient; Clinical Research; Collaborations; Communities; Complement; Development; Educational Activities; Environment; Evaluation; Funding; Funding Mechanisms; Goals; Grant; Human; Incidence; Institution; K-Series Research Career Programs; Laboratories; Leadership; Letters; Malignant neoplasm of prostate; Minority; Modeling; Monitor; National Cancer Institute; Participant; Peer Review Grants; Pilot Projects; Population; Principal Investigator; Process; Program Research Project Grants; Progress Reports; Publications; Qualifying; Quality of life; Recruitment Activity; Research; Research Personnel; Research Project Grants; Research Support; Scientist; Selection Criteria; Survival Rate; Translating; Translational Research; United States National Institutes of Health; Woman; Writing; anticancer research; base; cancer survival; career; flexibility; improved; innovation; meetings; member; mortality; organizational structure; programs; research study; success

PROJECT SUMMARY (Developmental Research Program) The goal of the Developmental Research Program (DRP) of the MD Anderson Cancer Center Prostate Cancer SPORE is to fund promising studies in translational prostate cancer research. It is directed by Dr. Timothy C. Thompson and co-directed by Dr. Christopher J. Logothetis. As with our current SPORE, the DRP in this renewal will emphasize the support of translational research studies that can generate clinically testable hypotheses to help reduce the incidence and mortality of prostate cancer and/or improve the quality of life of prostate cancer patients. The Prostate Cancer SPORE Administrative Core has established a broad-based effort for solicitation of potential DRP projects. Letters of intent of no more than 2 pages for innovative translational research are invited from MD Anderson and outside institutions and SPORE and non-SPORE investigators, including participants in the SPORE Career Enhancement Program. These applications will be screened by the program Director and co-Director (who also serve as the SPORE Principal investigator and co-Principal Investigator) according to objective criteria. Investigators of selected applications will be asked to prepare a 5-page proposal modeled after a National Institutes of Health R01. As appropriate, the Administrative Core Directors and staff will assist investigators submitting proposals formulate translational specific aims and research plans, as many of these investigators will not have expertise in these areas. The process constitutes a major educational activity and will further stimulate the development of innovative translational research concepts. The proposals will be reviewed and prioritized by the Prostate Cancer SPORE Leaders (Principal Investigators, Project co-Leaders, Program Directors, and Core Directors). The projects will be funded for 1 year and will be renewable for an additional year on the basis of established criteria. Developmental Research projects will be evaluated ad hoc and annually by the program Director/co- Director, SPORE Leaders, Executive Committee, and combined Internal/External Advisory Boards. The DRP has established a mechanism for termination of projects that do not meet our criteria for continuation; however, it has not been necessary to utilize this mechanism in the DRP to date. Nine developmental projects were funded in the current Prostate Cancer SPORE. Investigators receiving DRP grants wrote 29 publications related to the research supported by their grants during 2009-2014 and were awarded 19 external peer-reviewed grants. Importantly, 2 DRP awardees are investigators for major projects in the Prostate Cancer SPORE renewal application: Drs. Sue-Hwa Lin (co-Leader, Project 2) and Padmanee Sharma (co-Leader, Project 1), highlighting the importance of the DRP in identifying projects and investigators with potential value for translational research.

项目概要（发展研究计划） MD安德森癌症中心前列腺发展研究计划（DRP）的目标 癌症孢子是资助转化前列腺癌研究的有前途的研究。它是由博士。 蒂莫西·C由Christopher J. Logothetis博士共同执导。与我们当前的SPORE一样，DRP 在这次更新中，将强调对转化研究的支持， 有助于降低前列腺癌的发病率和死亡率和/或改善患者生活质量的假设 前列腺癌患者。前列腺癌孢子管理核心已经建立了一个基础广泛的 努力征集潜在的DRP项目。创新的意向书不超过2页 转化研究邀请MD安德森和外部机构以及SPORE和非SPORE 调查人员，包括SPORE职业提升计划的参与者。这些应用程序将 由项目主任和联合主任（他们也是SPORE的首席研究员， 共同主要研究者）。选定申请的研究者将被要求 准备一份5页的提案，仿照美国国立卫生研究院的R 01。各自在适当情况 行政核心主任和工作人员将协助研究人员提交建议，制定翻译 具体目标和研究计划，因为这些研究人员中有许多人在这些领域没有专门知识。的 过程构成了一个主要的教育活动，将进一步刺激创新的发展， 翻译研究概念。这些建议将由前列腺癌委员会审查和优先考虑。 SPORE领导者（主要研究者、项目共同领导者、项目总监和核心总监）。的 项目将获得一年的资助，并将在既定的基础上再延长一年。 的搜索.发展研究项目将由项目主任/合作伙伴进行临时评估和年度评估。 董事、SPORE领导人、执行委员会和内部/外部联合顾问委员会。的DRP 建立了一个机制，终止不符合我们继续执行标准的项目; 然而，到目前为止，还没有必要在难民遣返方案中利用这一机制。 目前的前列腺癌孢子资助了九个发展项目。接受DRP的研究者 2009-2014年期间，赠款撰写了29篇与其赠款支持的研究相关的出版物， 授予19项外部同行评审赠款。重要的是，2名DRP获奖者是重大项目的调查员 在前列腺癌孢子更新申请中：Sue-Hwa Lin博士（项目2共同负责人）和Padmanee博士 Sharma（项目1联合负责人），强调了DRP在确定项目和调查人员方面的重要性 具有潜在的转化研究价值。